Literature DB >> 17419227

Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma.

Junichiro Kawamura1, Yutaka Shimada, Hidenori Kitaichi, Izumi Komoto, Yosuhe Hashimoto, Junichi Kaganoi, Masayuki Miyake, Seiji Yamasaki, Kan Kondo, Masayuki Imamura.   

Abstract

BACKGROUND/AIMS: Aminopeptidase N (APN)/CD13 is a transmembrane ectoenzyme occurring in a wide variety of cells. Recently, APN/CD13 has been reported to be involved in tumor invasion and metastasis. However, precise functions in tumor cells, and its role in gastric carcinoma remain unclear.
METHODOLOGY: To evaluate the role of APN/CD13 in gastric carcinoma, we conducted immunohistochemical staining for APN/CD13 in 121 gastric carcinoma specimens, using anti-APN monoclonal antibody. The relationship between APN/CD13 expression and various prognostic factors of gastric carcinoma were investigated.
RESULTS: Of the 121 patients with gastric carcinoma studied, 48 were strongly positive, 36 were weakly positive, and 37 were negative. Overall survival rate of the patients with negative APN/CD13 expression was significantly lower than that of the patients with positive APN/CD13 expression. APN/CD13 expression was negatively associated with lymph node metastasis. Multivariate analysis showed APN/CD13 expression to be a significant prognostic factor.
CONCLUSIONS: Decreased expression of APN/CD13 was associated with a poor prognosis. Hence, our results demonstrate that the immunohistochemical detection of APN/CD13 could provide useful information as one of the prognostic factors in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17419227

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

1.  Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.

Authors:  Li Su; Jiangying Cao; Yuping Jia; Xiaonan Zhang; Hao Fang; Wenfang Xu
Journal:  ACS Med Chem Lett       Date:  2012-09-21       Impact factor: 4.345

2.  Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.

Authors:  Paola Di Matteo; Gian Luigi Arrigoni; Luca Alberici; Angelo Corti; Corrado Gallo-Stampino; Catia Traversari; Claudio Doglioni; Gian-Paolo Rizzardi
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

3.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

4.  Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.

Authors:  Kristina Viktorsson; Carl-Henrik Shah; Therese Juntti; Petra Hååg; Katarzyna Zielinska-Chomej; Adam Sierakowiak; Karin Holmsten; Jessica Tu; Jack Spira; Lena Kanter; Rolf Lewensohn; Anders Ullén
Journal:  Mol Oncol       Date:  2016-01-02       Impact factor: 6.603

5.  CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.

Authors:  Stefano Marletta; Claudio Luchini; Nicola Sperandio; Evelin Torresani; Alessandro Sorio; Ilaria Girolami; Aldo Scarpa; Albino Eccher; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2022-02-25       Impact factor: 4.535

6.  SEPROGADIC - serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy.

Authors:  Hee-Sung Ahn; Tae Sung Sohn; Mi Jeong Kim; Byoung Kyu Cho; Su Mi Kim; Seung Tae Kim; Eugene C Yi; Cheolju Lee
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

Review 7.  Aminopeptidase N (CD13) as a target for cancer chemotherapy.

Authors:  Malin Wickström; Rolf Larsson; Peter Nygren; Joachim Gullbo
Journal:  Cancer Sci       Date:  2011-01-30       Impact factor: 6.716

8.  Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13.

Authors:  Xuejian Wang; Fanbo Jing; Huawei Zhu; Hao Fang; Jian Zhang; Wenfang Xu
Journal:  Fundam Clin Pharmacol       Date:  2011-04       Impact factor: 2.748

9.  Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.

Authors:  K D Sørensen; M O Abildgaard; C Haldrup; B P Ulhøi; H Kristensen; S Strand; C Parker; S Høyer; M Borre; T F Ørntoft
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.